Participants in a randomized controlled trial had longer overall survival than non-participants

a prospective cohort study

Shinji Ohno, Hirofumi Mukai, Kazutaka Narui, Yasuo Hozumi, Yasuo Miyoshi, Hiroshi Yoshino, Hiroyoshi Doihara, Akihiko Suto, Motoshi Tamura, Takashi Morimoto, Hisamitsu Zaha, Takashi Chishima, Reiki Nishimura, Takashi Ishikawa, Yukari Uemura, Yasuo Ohashi

Research output: Contribution to journalArticle

Abstract

Purpose: While some studies show improved outcomes in clinical trial participants as compared to non-participants, existence of such a trial effect has not been proved precisely. Methods: This was a prospective cohort study to compare the prognoses for participants in the randomized controlled trial (SELECT BC) and non-participants. SELECT BC compared S-1 and taxane as first-line treatment for metastatic breast cancer. Non-participants were all patients who met the eligibility criteria of SELECT BC and who had been requested to participate in that trial by attending doctors and declined. The study aimed to compare the prognoses between participants and non-participants. The primary endpoint was median overall survival. Results: The median OS in participants was significantly superior to that in non-participants with a statistically significant difference (36.8 months vs. 25.2 months. HR 1.48, p = 0.022). A similar result was obtained when only patients who received the same chemotherapy (S-1 or taxane) used in SELECT BC after declining participation were assumed as non-participants (36.8 months vs. 22.0 months. HR 2.03, p = 0.006). Conclusions: This study may suggest the existence of a trial effect, in which, for a given treatment, participation in a clinical trial is associated with a better outcome.

Original languageEnglish
JournalBreast Cancer Research and Treatment
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Cohort Studies
Randomized Controlled Trials
Clinical Trials
Prospective Studies
Survival
Breast Neoplasms
Drug Therapy
Therapeutics
taxane

Keywords

  • Overall survival
  • Prospective cohort study
  • Randomized control trial
  • SELECT BC
  • Trial effect

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Participants in a randomized controlled trial had longer overall survival than non-participants : a prospective cohort study. / Ohno, Shinji; Mukai, Hirofumi; Narui, Kazutaka; Hozumi, Yasuo; Miyoshi, Yasuo; Yoshino, Hiroshi; Doihara, Hiroyoshi; Suto, Akihiko; Tamura, Motoshi; Morimoto, Takashi; Zaha, Hisamitsu; Chishima, Takashi; Nishimura, Reiki; Ishikawa, Takashi; Uemura, Yukari; Ohashi, Yasuo.

In: Breast Cancer Research and Treatment, 01.01.2019.

Research output: Contribution to journalArticle

Ohno, S, Mukai, H, Narui, K, Hozumi, Y, Miyoshi, Y, Yoshino, H, Doihara, H, Suto, A, Tamura, M, Morimoto, T, Zaha, H, Chishima, T, Nishimura, R, Ishikawa, T, Uemura, Y & Ohashi, Y 2019, 'Participants in a randomized controlled trial had longer overall survival than non-participants: a prospective cohort study', Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-019-05276-y
Ohno, Shinji ; Mukai, Hirofumi ; Narui, Kazutaka ; Hozumi, Yasuo ; Miyoshi, Yasuo ; Yoshino, Hiroshi ; Doihara, Hiroyoshi ; Suto, Akihiko ; Tamura, Motoshi ; Morimoto, Takashi ; Zaha, Hisamitsu ; Chishima, Takashi ; Nishimura, Reiki ; Ishikawa, Takashi ; Uemura, Yukari ; Ohashi, Yasuo. / Participants in a randomized controlled trial had longer overall survival than non-participants : a prospective cohort study. In: Breast Cancer Research and Treatment. 2019.
@article{4b43b62079cb495e803ade66c1f3c93b,
title = "Participants in a randomized controlled trial had longer overall survival than non-participants: a prospective cohort study",
abstract = "Purpose: While some studies show improved outcomes in clinical trial participants as compared to non-participants, existence of such a trial effect has not been proved precisely. Methods: This was a prospective cohort study to compare the prognoses for participants in the randomized controlled trial (SELECT BC) and non-participants. SELECT BC compared S-1 and taxane as first-line treatment for metastatic breast cancer. Non-participants were all patients who met the eligibility criteria of SELECT BC and who had been requested to participate in that trial by attending doctors and declined. The study aimed to compare the prognoses between participants and non-participants. The primary endpoint was median overall survival. Results: The median OS in participants was significantly superior to that in non-participants with a statistically significant difference (36.8 months vs. 25.2 months. HR 1.48, p = 0.022). A similar result was obtained when only patients who received the same chemotherapy (S-1 or taxane) used in SELECT BC after declining participation were assumed as non-participants (36.8 months vs. 22.0 months. HR 2.03, p = 0.006). Conclusions: This study may suggest the existence of a trial effect, in which, for a given treatment, participation in a clinical trial is associated with a better outcome.",
keywords = "Overall survival, Prospective cohort study, Randomized control trial, SELECT BC, Trial effect",
author = "Shinji Ohno and Hirofumi Mukai and Kazutaka Narui and Yasuo Hozumi and Yasuo Miyoshi and Hiroshi Yoshino and Hiroyoshi Doihara and Akihiko Suto and Motoshi Tamura and Takashi Morimoto and Hisamitsu Zaha and Takashi Chishima and Reiki Nishimura and Takashi Ishikawa and Yukari Uemura and Yasuo Ohashi",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s10549-019-05276-y",
language = "English",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",

}

TY - JOUR

T1 - Participants in a randomized controlled trial had longer overall survival than non-participants

T2 - a prospective cohort study

AU - Ohno, Shinji

AU - Mukai, Hirofumi

AU - Narui, Kazutaka

AU - Hozumi, Yasuo

AU - Miyoshi, Yasuo

AU - Yoshino, Hiroshi

AU - Doihara, Hiroyoshi

AU - Suto, Akihiko

AU - Tamura, Motoshi

AU - Morimoto, Takashi

AU - Zaha, Hisamitsu

AU - Chishima, Takashi

AU - Nishimura, Reiki

AU - Ishikawa, Takashi

AU - Uemura, Yukari

AU - Ohashi, Yasuo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: While some studies show improved outcomes in clinical trial participants as compared to non-participants, existence of such a trial effect has not been proved precisely. Methods: This was a prospective cohort study to compare the prognoses for participants in the randomized controlled trial (SELECT BC) and non-participants. SELECT BC compared S-1 and taxane as first-line treatment for metastatic breast cancer. Non-participants were all patients who met the eligibility criteria of SELECT BC and who had been requested to participate in that trial by attending doctors and declined. The study aimed to compare the prognoses between participants and non-participants. The primary endpoint was median overall survival. Results: The median OS in participants was significantly superior to that in non-participants with a statistically significant difference (36.8 months vs. 25.2 months. HR 1.48, p = 0.022). A similar result was obtained when only patients who received the same chemotherapy (S-1 or taxane) used in SELECT BC after declining participation were assumed as non-participants (36.8 months vs. 22.0 months. HR 2.03, p = 0.006). Conclusions: This study may suggest the existence of a trial effect, in which, for a given treatment, participation in a clinical trial is associated with a better outcome.

AB - Purpose: While some studies show improved outcomes in clinical trial participants as compared to non-participants, existence of such a trial effect has not been proved precisely. Methods: This was a prospective cohort study to compare the prognoses for participants in the randomized controlled trial (SELECT BC) and non-participants. SELECT BC compared S-1 and taxane as first-line treatment for metastatic breast cancer. Non-participants were all patients who met the eligibility criteria of SELECT BC and who had been requested to participate in that trial by attending doctors and declined. The study aimed to compare the prognoses between participants and non-participants. The primary endpoint was median overall survival. Results: The median OS in participants was significantly superior to that in non-participants with a statistically significant difference (36.8 months vs. 25.2 months. HR 1.48, p = 0.022). A similar result was obtained when only patients who received the same chemotherapy (S-1 or taxane) used in SELECT BC after declining participation were assumed as non-participants (36.8 months vs. 22.0 months. HR 2.03, p = 0.006). Conclusions: This study may suggest the existence of a trial effect, in which, for a given treatment, participation in a clinical trial is associated with a better outcome.

KW - Overall survival

KW - Prospective cohort study

KW - Randomized control trial

KW - SELECT BC

KW - Trial effect

UR - http://www.scopus.com/inward/record.url?scp=85066125154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066125154&partnerID=8YFLogxK

U2 - 10.1007/s10549-019-05276-y

DO - 10.1007/s10549-019-05276-y

M3 - Article

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

ER -